NCT07428447Recruiting
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 13 Feb 2026
- Start date
- 18 Feb 2026
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- CND Life Sciences
- Diseases
- Parkinson disease
- NCT number
- NCT07428447
What you commit to
- Study type: Observational
- Planned participants: 300
- From 18 Feb 2026 to the primary completion date, 28 Feb 2027
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participant is currently receiving treatment with carbidopa-levodopa for PD
- Prior to enrollment, receipt of an intracranial procedure intended to treat tremor or parkinsonism, including thalamic deep brain stimulation (DBS) implantation or focused ultrasound (FUS) thalamotomy. Other prior intracranial surgery is exclusionary only when, in the investigator's or Sponsor's Chief Medical Officer's judgment, it could materially affect motor assessments, diagnostic classification, participant safety, or interpretation of study outcomes.
Other illness
- Clinical evidence of severe peripheral vascular disease
- Clinically active coronary artery or cerebrovascular disease
- Allergic reaction to local anesthesia
- History of or increased risk for impaired wound healing, scarring, or keloid formation
- History of other neurodegenerative disorder or evidence of neurological co-pathology
Lab values
- Participant is currently on anticoagulant or dual anti-platelet therapy
Age
- Under age 50, Over age 85
Other
- Alcoholism
- Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise
- Abnormal DaTscan
- Isolated focal tremors (head, voice)
- Task-specific tremor (e.g., primary writing tremor)
- Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET
- Sudden onset and step-wise deterioration
Who the study is looking for
- Age 50-85 years old
- Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR
- Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here."
- Willing to participate in all study procedures
- Able and willing to provide written informed consent
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| QUEST Research Institute Coordinator of this site? Confirm its status | Farmington Hills | United States | Recruiting |
| University of Kansas Medical Center Coordinator of this site? Confirm its status | Kansas City | United States | Not yet recruiting |
| Norton Healthcare Coordinator of this site? Confirm its status | Louisville | United States | Recruiting |
| Veracity Neurosciences LLC Coordinator of this site? Confirm its status | Memphis | United States | Recruiting |
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Not yet recruiting |
| Neurology One Coordinator of this site? Confirm its status | Orlando | United States | Recruiting |
| CND Clinical Research Center Coordinator of this site? Confirm its status | Scottsdale | United States | Recruiting |
| Movement Disorders Center of Arizona Coordinator of this site? Confirm its status | Scottsdale | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.